Table 2– Overall and disease-free survival in dependence of clinicopathological, diagnostic and predictive biomarkers

	Overall survival				Disease-free survival
	Cases	Events	Survival months	p-value	Cases	Events	Survival months	p-value
Age
Below mean	196	80	65.32±3.43	0.644	196	101	50.67±3.46	0.006
Above mean	229	99	60.91±3.17		229	84	63.12±3.52
Sex
Male	264	123	59.76±2.94	0.024	264	124	53.00±3.06	0.045
Female	161	56	69.35±3.77		161	61	64.06±4.12
Smoking status
Never-smoker	34	8	57.05±3.44	0.068	34	15	41.39±5.03	0.959
Smoker	332	144	62.23±2.68		332	148	55.04±2.80
UICC stage
I	176	41	83.07±3.17		176	42	79.18±3.28
II	94	43	61.05±4.60	<0.001	94	51	47.99±4.89	<0.001
III	143	87	41.65±3.68		143	85	34.70±3.83
IV	12	8	20.25±4.06		12	7	16.10±5.20
Tumour stage
T1	78	15	82.12±4.92		78	17	77.23±5.35
T2	268	122	61.91±2.85	<0.001	268	120	56.95±3.04	<0.001
T3	67	34	54.69±5.83		67	41	37.47±5.70
T4	12	8	37.32±11.14		12	7	17.50±4.14
Nodal status
N0	230	63	79.27±2.89		230	74	70.70±3.11
N1	76	44	49.44±5.04	<0.001	76	41	45.17±5.84	<0.001
N2	116	71	40.36±4.03		116	69	31.66±3.51
N3	3	1	13.13±0.00		3	1	8.82±1.87
Distant metastases
M0	413	171	64.42±2.37	<0.001	413	178	58.12±2.52	0.006
M1	12	8	20.25±4.06		12	7	16.10±5.20
Pattern
Lepidic	30	8	70.21±6.60		30	10	65.74±7.00
Acinar	176	72	65.96±3.52	0.071	176	72	60.92±3.78	0.051
Solid	149	72	56.36±3.83		149	71	50.68±4.22
Papillary	21	10	46.16±7.45		21	12	35.12±6.63
Micropapillary	25	11	47.19±6.96		25	13	38.20±7.29
Type
Conventional	416	178	62.64±2.37	0.046	416	185	56.11±2.53	0.009
Invasive mucinous	9	1	87.04±8.51		9	0
CK7
Negative	14	5	48.66±5.85	0.569	14	7	35.45±7.14	0.701
Positive	404	171	63.27±2.40		404	177	57.10±2.55
TTF1
Negative	52	26	49.80±61.09	0.030	52	26	43.61±6.51	0.045
Positive	366	150	64.75±24.99		366	157	58.50±2.67
Napsin
Negative	103	48	58.04±4.68	0.160	103	51	50.67±4.96	0.056
Positive	317	129	64.84±2.69		317	133	58.97±2.89
ERCC1
Below mean	198	84	62.24±3.51	0.509	198	94	52.30±3.62	0.072
Above mean	186	79	63.98±3.40		186	78	59.44±3.75
TS
Below mean	208	95	56.35±3.31	0.005	208	102	49.29±3.53	<0.001
Above mean	187	66	71.84±3.43		187	66	65.85±3.88
*ALK*
Negative	419	178	63.30±2.35	0.387	419	183	57.41±2.52	0.615
Positive	6	1	47.88±7.84		6	2	50.05±4.22
*KRAS*
Wild-type	265	111	64.28±2.90	0.464	265	114	58.96±3.10	0.302
Mutant	160	68	59.76±3.55		160	71	52.24±3.94
*BRAF*
Wild-type	408	170	63.81±2.40	0.398	408	172	59.19±2.55	0.009
Mutant	17	9	55.13±10.92		17	13	29.47±6.16
EGFR total
Wild-type	359	150	63.85±2.55	0.777	359	154	57.78±2.71	0.529
Mutant	66	29	60.38±5.72		66	31	54.92±6.46
EGFR exon 18
Wild-type	419	174	64.13±2.36	0.025	419	181	57.80±2.52	0.108
Mutant	6	5	30.79±10.24		6	4	17.98±5.09
EGFR exon 19
Wild-type	398	169	63.16±2.43	0.543	398	170	58.19±2.59	0.214
Mutant	27	10	67.82±8.73		27	15	46.96±9.07
EGFR exon 20
Wild-type	413	172	63.88±2.38	0.317	413	179	57.48±2.54	0.626
Mutant	12	7	52.41±11.95		12	6	55.90±13.95
EGFR exon 21
Wild-type	398	167	63.62±2.43	0.912	398	174	57.10±2.58	0.705
Mutant	27	12	54.23±6.77		27	11	54.28±7.45

Data are presented as n or mean±se, unless otherwise stated. p-values were calculated using a log-rank test. UICC: Union for International Cancer Control; CK: cytokeratin; TTF: thyroid transcription factor; ERCC1: excision repair cross-complementing rodent repair deficiency complementation group 1 protein; TS: thymidylate synthase; ALK: anaplastic lymphoma kinase; KRAS: V-Ki-ras2 Kirsten rat sarcoma viral oncogene homologue; BRAF: v-Raf murine sarcoma viral oncogene homologue B1; EGFR: epidermal growth factor receptor.